Continued ovarian stimulation after premature LH surge with oocyte retrieval and embryo cryopreservation performed in the luteal phase for fertility preservation prior to breast cancer treatment

2008 ◽  
Vol 90 ◽  
pp. S449-S450 ◽  
Author(s):  
A. Lee ◽  
S.G. Somkuti ◽  
L.I. Barmat ◽  
S.E. Smith ◽  
J.S. Schinfeld
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Fertility Preservation ◽  
Ovarian Stimulation ◽  
Luteal Phase ◽  
Oocyte Retrieval ◽  
Breast Cancer Treatment ◽  
Embryo Cryopreservation ◽  
Lh Surge ◽  
Premature Lh Surge

Fertility preservation for women undergoing breast cancer treatment: A postcode lottery?

2020 ◽  
Vol 26 (10) ◽  
pp. 2117-2118
Author(s):  
Isabella Dash ◽  
Belinda C.S. Pearce ◽  
Sarah Armstrong ◽  
Christobel Saunders ◽  
Allan Pacey
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Fertility Preservation ◽  
Breast Cancer Treatment

scholarly journals Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer

2015 ◽  
Vol 33 (22) ◽  
pp. 2424-2429 ◽  
Author(s):  
Kutluk Oktay ◽  
Volkan Turan ◽  
Giuliano Bedoschi ◽  
Fernanda S. Pacheco ◽  
Fred Moy
Keyword(s):  
Breast Cancer ◽  
In Vitro Fertilization ◽  
Fertility Preservation ◽  
Embryo Transfer ◽  
Ovarian Stimulation ◽  
Live Birth Rate ◽  
Embryo Cryopreservation ◽  
Vitro Fertilization ◽  
Embryo Freezing

Purpose We have previously reported an approach to ovarian stimulation for the purpose of fertility preservation (FP) in women with breast cancer via embryo freezing with the concurrent use of letrozole. The aim of this study was to provide the pregnancy and FP outcomes when embryos generated with the same protocol are used. Patients and Methods In all, 131 women with stage ≤ 3 breast cancer underwent ovarian stimulation and received concurrent letrozole 5 mg per day before receiving adjuvant chemotherapy and cryopreserving embryos. Results Thirty-three of the 131 women underwent 40 attempts to transfer embryos to their own uterus (n = 18) or via the use of a gestational carrier (n = 22) at a mean age of 41.5 ± 4.3 years with a median 5.25 years after embryo cryopreservation. The overall live birth rate per embryo transfer was similar to the US national mean among infertile women of a similar age undergoing in vitro fertilization–embryo transfer (45.0 v 38.2; P = .2). Seven (38.8%) of the 18 pregnancies were twins with no higher-order pregnancies being encountered. No fetal anomalies or malformations were reported in 25 children after a mean follow-up of 40.4 ± 26.4 months. Seventeen of the 33 women attempting pregnancy had at least one child, translating into an FP rate of 51.5% per attempting woman. Conclusion Embryo cryopreservation after ovarian stimulation with the letrozole and follicle-stimulating hormone protocol preserves fertility in women with breast cancer and results in pregnancy rates comparable to those expected in a noncancer population undergoing in vitro fertilization.

scholarly journals Relative Potencies of Anastrozole and Letrozole to Suppress Estradiol in Breast Cancer Patients Undergoing Ovarian Stimulation before in Vitro Fertilization

2007 ◽  
Vol 92 (6) ◽  
pp. 2197-2200 ◽  
Author(s):  
Amr A. Azim ◽  
Maria Costantini-Ferrando ◽  
K. Lostritto ◽  
Kutluk Oktay
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Ovarian Stimulation ◽  
Area Under The Curve ◽  
Oocyte Retrieval ◽  
Embryo Cryopreservation ◽  
Breast Cancer Patients ◽  
Vitro Fertilization ◽  
The Mean

Abstract Context: Breast cancer patients undergoing controlled ovarian hyperstimulation (COH) for embryo or oocyte cryopreservation should be induced by the method that leads to the least increase in estradiol (E2) levels. Objective: The aim of the study was to determine the potency of anastrozole to suppress serum E2 levels in breast cancer patients undergoing COH. Design and Setting: A prospective sequential cohort study was conducted in an academic center for reproductive medicine between May 2003 and November 2005 for letrozole and between December 2005 and April 2006 for anastrozole. Patients: Breast cancer patients presenting for fertility preservation participated in the study. Intervention: COH using FSH and letrozole (n = 47) or anastrozole (n = 7) was followed by oocyte retrieval and embryo cryopreservation. Main Outcome Measures: Serum E2 levels, area under the curve for E2, and outcomes of COH cycles were measured. Results: There were no significant differences between the two groups regarding length of stimulation, total gonadotropin dose, number of follicles larger than 17 mm, and the lead follicle size on human chorionic gonadotropin (hCG) day and number of embryos cryopreserved. The mean E2 levels on the day of hCG and post-hCG days were higher in the anastrozole group compared to the letrozole group (1325.89 ± 833.17 and 2515.07 ± 1368.52 vs. 427.78 ± 278.24 and 714.38 ± 440.83 pg·d/ml; P ≤ 0.01), respectively, even when anastrozole dose was increased up to 10 mg/d. The mean area under the curve was significantly higher in the anastrozole group compared to the letrozole group (4402.93 ± 1526.7 vs. 1287.48 ± 732.17 pg·d/ml; P <0.004). Conclusions: Breast cancer patients who underwent ovarian stimulation with anastrozole had a significantly higher exposure to E2 than those who were stimulated with letrozole.

scholarly journals A retrospective study evaluating the impact of scattering radiation from imaging procedures on oocyte quality during ovarian stimulation for fertility preservation in young breast cancer patients

2021 ◽  
Author(s):  
Margherita Condorelli ◽  
Maëlle Sens ◽  
Ornit Goldrat ◽  
Anne Delbaere ◽  
Judith Racapé ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Retrospective Study ◽  
Ionizing Radiation ◽  
Cancer Patients ◽  
Fertility Preservation ◽  
Ovarian Stimulation ◽  
Oocyte Quality ◽  
Embryo Cryopreservation ◽  
Breast Cancer Patients ◽  
Young Breast Cancer

Abstract Purpose Ovarian stimulation for oocyte and embryo cryopreservation is the standard of care for fertility preservation in young breast cancer patients before gonadotoxic chemotherapy. The procedure should be started as soon as possible to avoid delay of treatment; thus, it is often performed concomitantly with tumor staging assessments. However, questions remain regarding the potential negative impact on oocyte quality that may occur due to exposure to scattered ionizing radiation from imaging techniques when staging assessment is conducted at the same time as ovarian stimulation. Methods We conducted a retrospective study on all breast cancer patients who received ovarian stimulation for fertility preservation at our center between November, 2012 and May, 2020. Results Gynecologic and oncologic characteristics were similar between patients exposed (n = 14) or not (n = 60) to ionizing radiation. Exposed patients started the ovarian stimulation sooner after diagnosis than non-exposed patients (11.5 vs 28 days, respectively, P < 0.01). Cycle parameters, including the median number of oocytes collected (10.5 vs 7, P = 0.16), maturation rates (92.5% vs 85.7%, P = 0.54), and fertilization rates (62.2% vs 65.4%, P = 0.70) were similar between groups. Conclusions This study shows that scattered ionizing radiation due to staging assessment appears to be safe without compromising follicular growth and maturation. Larger studies on fertility and obstetrical outcomes are needed to confirm these preliminary data.

Puerperal Fertility Preservation with Controlled Ovarian Stimulation and Embryo Cryopreservation for Pregnancy-Associated Breast Cancer

2015 ◽  
Vol 31 (3) ◽  
pp. 173-176 ◽  
Author(s):  
Radhika S. Datar ◽  
Nigel Pereira ◽  
Sharon H. Anderson ◽  
Jacob Stillman ◽  
Michael J. Glassner
Keyword(s):  
Breast Cancer ◽  
Fertility Preservation ◽  
Ovarian Stimulation ◽  
Controlled Ovarian Stimulation ◽  
Embryo Cryopreservation
Sign in / Sign up

Export Citation Format

Share Document